Navigation Links
Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution

COLUMBUS, Ohio, July 14 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its New Drug Application (NDA) for Morphine Sulfate Tablets and Oral Solution CII by the U.S. Food and Drug Administration. Roxane Laboratories' Morphine Sulfate CII is available in 15mg, 30mg tablet strengths and 10mg/5mL, 20mg/5mL oral solution strengths. Roxane Laboratories' Morphine Sulfate tablets and oral solutions CII are currently available for immediate shipment to wholesalers and pharmacies nationwide.

(Logo: )

With this New Drug Application approval, Roxane Laboratories has the only FDA approved Morphine Sulfate Immediate Release Tablets and Oral Solution available for distribution in the United States.

Full prescribing information for Morphine Sulfate is available on the Roxane Laboratories website at or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit

SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
2. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
3. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
4. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
11. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... SPH Analytics today announced the following ... Executive Vice President of Operations, and three Senior Vice Presidents, Robert Davis, David ... company. , Debbie Vereb’s appointment to Executive Vice President of Operations at SPH ...
(Date:10/13/2015)... ... 2015 , ... Curly Hair Solutions® is thrilled to be ... exhibition featuring the newest products and services to hit the market for women. ... excited to unveil their recent partnership with Trade Secrets, a leading Canadian beauty ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory test for bacterial ... of Gynecology and Obstetrics in Vancouver, BC, Canada. , In a ...
(Date:10/13/2015)... ... October 13, 2015 , ... Doulagivers is O'Brien's ... Training and End of Life Doula Training. A Doulagiver is a non-medical ... and emotionally. Based on her #1 International bestselling book Creating Positive Passings ...
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, ... the release of its new Professional Medical Coding and Billing with Applied PCS ... ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology: